The finding of SPARC protein in pancreatic cancer patients, also described by other investigators, was the basis for this phase I clinical trial that Von Hoff presented at AACR.
Chemotherapy often means combining more than one drug, and we do not want to just take the next thing off the shelf. We want to know as much about a tumor as possible going in, Von Hoff said.
Researchers reported on the first 20 patients of what will eventually be a 42-patient trial.
This was a phase I trial, and phase I trials are usually designed to test safety, hoping it will also determine efficacy. The fact that we saw this kind of activity in a phase I trial is dramatic, Von Hoff said.
The rationale behind the combination of Gemcitabine plus Abraxane was based on careful science and was designed and executed by some of the leading experts in pancreas cancer in the world. While the data is preliminary and longer follow-up will be important, the biochemical and radiographic responses look very encouraging, says Dr. Laheru of Johns Hopkins Kimmel Cancer Center.
|Contact: Galen Perry|
The Translational Genomics Research Institute